查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930086

全球多发性骨髓瘤市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Multiple Myeloma Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 110 Pages | 商品交期: 请询问到货日

价格

多发性骨髓瘤市场成长因素

预计2025年全球多发性骨髓瘤市场规模将达到292.4亿美元，并从2026年的310亿美元增长至2034年的441.9亿美元，预测期内复合年增长率（CAGR）为6.10%。北美地区将在2025年占58.28%的市场占有率，这主要得益于该地区较高的疾病诊断率、先进疗法的积极应用以及众多大型肿瘤公司的参与。

多发性骨髓瘤（MM）是一种罕见但严重的血液癌症，其特征是浆细胞不受控制地增殖。如果不及时治疗，可能致命。对疾病症状的认识不断提高、早期诊断的普及以及标靶治疗和免疫疗法的快速发展，显着改善了疾病管理，推动了全球市场成长。

市场概览及主要亮点

  • 市场规模（2025年）：292.4亿美元
  • 市场规模（2026年）：310亿美元
  • 市场规模（2034年）：441.9亿美元
  • 复合年增长率：6.10%
  • 主要地区：北美（市占率：58.28%（2025年））
  • 主要药物类别：免疫调节剂

市场趋势

强大的在研药物推动成长

推动多发性骨髓瘤市场发展的关键趋势之一是强大的新型疗法研发管线。製药公司正大力投资研发，以满足尚未满足的医疗需求。多个前景可观的在研药物正处于不同的临床开发阶段。例如，再生元公司的 REGN5458 (BCMAXCD3) 已展现出积极的临床结果，凸显了双特异性抗体和标靶疗法日益重要的作用。预计这些进展将在预测期内显着推动市场扩张。

市场驱动因素

多发性骨髓瘤发生率上升

包括多发性骨髓瘤在内的血液系统癌症发生率的上升是市场成长的主要驱动因素。儘管多发性骨髓瘤被归类为罕见癌症，但它在全球癌症病例中仍占有相当大的比例。根据癌症网络（Cancer Network）的统计数据，2016 年全球报告的多发性骨髓瘤病例约为 13 万例，且发生率持续上升。诊断能力的提高和公众意识的增强正在提高检出率，并推动对有效疗法的需求。

新产品上市及监管核准不断增加

持续的研发投入推动了新产品的频繁上市和监管审批，从而拓展了治疗选择。例如，2020 年 3 月，美国食品药物管理局 (FDA) 批准了 Sarcrysa（isatuximab-IRFC）作为復发或难治性多发性骨髓瘤患者的联合疗法。儘管治癒率仍然有限，但疾病控制和预后的改善鼓励了更多患者接受治疗，从而提升了市场收入。

市场限制因子

治疗费用高

儘管治疗方法不断进步，但高昂的治疗费用仍然是一个重大障碍，尤其是在发展中国家。环磷酰胺的年治疗费用为 5,800 美元，而 Pomalyst 的年治疗费用约为 192,000 美元，这限制了患者获得先进疗法的机会。保险覆盖不足、认知度低以及支付机制不完善进一步限制了新兴市场治疗的普及。

市场区隔分析

依药物类别

到2026年，免疫调节药物将占市场主导地位，市占率将达到65.07%。瑞復美（Revlimid，新基/百时美施贵宝）等药物在实现良好的治疗效果方面发挥关键作用。其他主要细分市场包括蛋白酶体抑制剂、抗CD38单株抗体、烷化剂和XPO1抑制剂等新兴药物类别。

依分销管道

由于静脉输液治疗的高使用率以及对受控临床环境的需求，到2026年，医院药房将占最大的市场占有率，达到58.67%。儘管实体药局的成长速度有所放缓，但由于网路药局的便利性和处方配药的便利性，预计将保持稳定成长。

区域分析

  • 北美地区仍然是关键区域，这得益于其较高的诊断率、强劲的医疗保健支出以及先进疗法的广泛应用。
  • 欧洲受益于监管核准的增加和专利到期时间的延长。
  • 亚太地区展现出强劲的成长潜力，这得益于庞大的患者群体以及达雷妥尤单抗（Darzalex）等关键药物在日本的获准。
  • 拉丁美洲以及中东和非洲地区目前处于成长初期，但随着医疗保健基础设施的改善，预计将会进一步扩张。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇

第四章：关键考虑因素

  • 主要国家多发性骨髓瘤盛行率（2025 年）
  • 在开发产品分析
  • 主要行业趋势
  • 主要地区的监管环境
  • 多发性骨髓瘤治疗经济负担分析
  • 新产品上市
  • 多发性骨髓瘤新兴疗法概述

第五章 全球多发性骨髓瘤多发性骨髓瘤市场分析：洞察与预测 (2021-2034)

  • 关键分析/摘要
  • 市场分析、洞察与预测：依药物类别划分
    • 免疫调节剂
    • 蛋白酶体抑制剂
    • 抗CD38单株抗体
    • 烷化剂
    • 其他
  • 市场分析、洞察与预测：依销售管道划分
    • 医院药房
    • 零售药局和药局
    • 线上药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美多发性骨髓瘤多发性骨髓瘤市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲多发性骨髓瘤市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区多发性骨髓瘤市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲多发性骨髓瘤市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲多发性骨髓瘤市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）成员国
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 主要的产业趋势
  • 世界市场占有率分析(2017年)
  • 竞争形势仪表板
  • 主要企业的比较分析
  • 企业简介
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Bristol Myers Squibb Company
  • Amgen Inc.
  • ONO PHARMACEUTICAL CO., LTD.
  • Janssen Pharmaceuticals, Inc.
  • Genentech, Inc.(F． Hoffmann-La Roche Ltd)
  • CELGENE CORPORATION(Bristol Myers Squibb Company)
  • AbbVie Inc.
  • Sanofi
  • 其他的着名的企业

第12章 策略性建议

Product Code: FBI102693

Growth Factors of multiple myeloma Market

The global multiple myeloma market was valued at USD 29.24 billion in 2025 and is projected to grow from USD 31.00 billion in 2026 to USD 44.19 billion by 2034, registering a CAGR of 6.10% during the forecast period. North America dominated the market with a 58.28% share in 2025, supported by higher disease diagnosis rates, strong adoption of advanced therapeutics, and the presence of leading oncology companies.

Multiple myeloma (MM) is a rare but severe form of blood cancer characterized by the uncontrolled proliferation of plasma cells. If left untreated, the disease can be fatal. Rising awareness of disease symptoms, earlier diagnosis, and rapid advancements in targeted and immunotherapy-based treatments have significantly improved disease management, driving market growth globally.

Market Snapshot & Key Highlights

  • 2025 Market Size: USD 29.24 billion
  • 2026 Market Size: USD 31.00 billion
  • 2034 Market Size: USD 44.19 billion
  • CAGR: 6.10%
  • Dominant Region: North America (58.28% share in 2025)
  • Leading Drug Class: Immunomodulators

Market Trends

Strong Pipeline Candidates Driving Growth

One of the major trends shaping the multiple myeloma market is the robust pipeline of novel therapeutics. Pharmaceutical companies are heavily investing in R&D to address unmet clinical needs. Several promising pipeline candidates are in various stages of clinical development. For instance, Regeneron's REGN5458 (BCMAXCD3) has shown positive clinical outcomes, highlighting the growing role of bispecific antibodies and targeted therapies. These advancements are expected to significantly contribute to market expansion during the forecast period.

Market Drivers

Increasing Prevalence of Multiple Myeloma

The rising prevalence of blood cancers, including multiple myeloma, is a key driver of market growth. Although MM is classified as a rare cancer, it accounts for a substantial number of cancer cases worldwide. According to Cancer Network statistics, approximately 130,000 cases of multiple myeloma were reported globally in 2016, and incidence rates continue to rise. Improved diagnostic capabilities and increased awareness have led to higher detection rates, thereby increasing demand for effective treatment options.

Rising Product Launches and Regulatory Approvals

Continuous R&D efforts have resulted in frequent product launches and regulatory approvals, enhancing treatment availability. For example, in March 2020, the U.S. FDA approved Sarclisa (isatuximab-irfc) in combination therapy for patients with relapsed or refractory multiple myeloma. Although cure rates remain limited, improved disease management and better prognosis are encouraging more patients to seek treatment, boosting market revenue.

Market Restraint

High Cost of Treatment

Despite therapeutic advancements, high treatment costs remain a significant barrier, especially in developing economies. Annual treatment costs can range from USD 5,800 for cyclophosphamide to nearly USD 192,000 for Pomalyst, limiting access to advanced therapies. Lack of reimbursement coverage, limited awareness, and inadequate payment mechanisms further restrict treatment adoption in emerging markets.

Segmentation Analysis

By Drug Class

The immunomodulators segment dominated the market, accounting for 65.07% share in 2026. Drugs such as Revlimid (Celgene/Bristol Myers Squibb) have played a crucial role in achieving positive treatment outcomes. Other important segments include proteasome inhibitors, anti-CD38 monoclonal antibodies, alkylating agents, and emerging drug classes such as XPO1 inhibitors.

By Distribution Channel

Hospital pharmacies held the largest market share at 58.67% in 2026, due to the high use of intravenously administered therapies and the need for controlled clinical settings. Retail pharmacies registered slower growth, while online pharmacies are expected to grow steadily due to convenience and easier prescription fulfillment.

Regional Analysis

  • North America remains the leading region due to high diagnosis rates, strong healthcare expenditure, and advanced therapeutics adoption.
  • Europe benefits from increasing regulatory approvals and longer patent expiry timelines.
  • Asia Pacific shows strong growth potential, supported by large patient populations and approvals of key drugs such as DARZALEX in Japan.
  • Latin America and Middle East & Africa are in early growth stages but are expected to expand with improving healthcare infrastructure.

Competitive Landscape

The market is highly competitive, led by major oncology players such as Takeda, Bristol Myers Squibb, Amgen, Janssen, Genentech, AbbVie, Sanofi, and Karyopharm. Companies are focusing on product diversification, pipeline expansion, and regulatory approvals to strengthen their market position.

Conclusion

The global multiple myeloma market, valued at USD 29.24 billion in 2025, grew to USD 31.00 billion in 2026 and is projected to reach USD 44.19 billion by 2034. Market growth is driven by rising disease prevalence, strong R&D pipelines, increasing product approvals, and improved treatment outcomes. While high treatment costs remain a challenge, continuous innovation and expanding access to advanced therapies are expected to support sustained market growth during the forecast period.

Segmentation By Drug Class

  • Immunomodulators
  • Proteasome Inhibitor
  • Anti-CD38 Monoclonal Antibody
  • Alkylating Agents
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia-Pacific)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and the Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Multiple Myeloma - by Key Countries - 2025
  • 4.2. Pipeline Analysis
  • 4.3. Key Industry Developments
  • 4.4. Regulatory Scenario, by Key Regions
  • 4.5. Analysis Of Economic Burden of Multiple Myeloma Treatment
  • 4.6. New Product Launches
  • 4.7. Overview of Emerging Treatments for Multiple Myeloma

5. Global Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. Immunomodulators
    • 5.2.2. Proteasome Inhibitor
    • 5.2.3. Anti-CD38 Monoclonal Antibody
    • 5.2.4. Alkylating Agents
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies & Drug Stores
    • 5.3.3. Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Drug Class
    • 6.2.1. Immunomodulators
    • 6.2.2. Proteasome Inhibitor
    • 6.2.3. Anti-CD38 Monoclonal Antibody
    • 6.2.4. Alkylating Agents
    • 6.2.5. Others
  • 6.3. Market Analysis - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies & Drug Stores
    • 6.3.3. Online Pharmacies
  • 6.4. Market Analysis - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Drug Class
    • 7.2.1. Immunomodulators
    • 7.2.2. Proteasome Inhibitor
    • 7.2.3. Anti-CD38 Monoclonal Antibody
    • 7.2.4. Alkylating Agents
    • 7.2.5. Others
  • 7.3. Market Analysis - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies & Drug Stores
    • 7.3.3. Online Pharmacies
  • 7.4. Market Analysis - By Country/ sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia pacific Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Drug Class
    • 8.2.1. Immunomodulators
    • 8.2.2. Proteasome Inhibitor
    • 8.2.3. Anti-CD38 Monoclonal Antibody
    • 8.2.4. Alkylating Agents
    • 8.2.5. Others
  • 8.3. Market Analysis - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies & Drug Stores
    • 8.3.3. Online Pharmacies
  • 8.4. Market Analysis - By Country/ sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Drug Class
    • 9.2.1. Immunomodulators
    • 9.2.2. Proteasome Inhibitor
    • 9.2.3. Anti-CD38 Monoclonal Antibody
    • 9.2.4. Alkylating Agents
    • 9.2.5. Others
  • 9.3. Market Analysis - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies & Drug Stores
    • 9.3.3. Online Pharmacies
  • 9.4. Market Analysis - By Country/ sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Multiple Myeloma Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Drug Class
    • 10.2.1. Immunomodulators
    • 10.2.2. Proteasome Inhibitor
    • 10.2.3. Anti-CD38 Monoclonal Antibody
    • 10.2.4. Alkylating Agents
    • 10.2.5. Others
  • 10.3. Market Analysis - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies & Drug Stores
    • 10.3.3. Online Pharmacies
  • 10.4. Market Analysis - By Country/ sub-region
    • 10.4.1. GCC Countries
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2017)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.5.1. Takeda Pharmaceutical Company Limited
      • 11.5.1.1. Overview,
      • 11.5.1.2. Products & services,
      • 11.5.1.3. SWOT analysis,
      • 11.5.1.4. Recent developments,
      • 11.5.1.5. strategies,
      • 11.5.1.6. financials (based on availability)
    • 11.5.2. Novartis AG
      • 11.5.2.1. Overview,
      • 11.5.2.2. Products & services,
      • 11.5.2.3. SWOT analysis,
      • 11.5.2.4. Recent developments,
      • 11.5.2.5. strategies,
      • 11.5.2.6. financials (based on availability)
    • 11.5.3. Teva Pharmaceutical Industries Ltd.
      • 11.5.3.1. Overview,
      • 11.5.3.2. Products & services,
      • 11.5.3.3. SWOT analysis,
      • 11.5.3.4. Recent developments,
      • 11.5.3.5. strategies,
      • 11.5.3.6. financials (based on availability)
    • 11.5.4. Bristol Myers Squibb Company
      • 11.5.4.1. Overview,
      • 11.5.4.2. Products & services,
      • 11.5.4.3. SWOT analysis,
      • 11.5.4.4. Recent developments,
      • 11.5.4.5. strategies,
      • 11.5.4.6. financials (based on availability)
    • 11.5.5. Amgen Inc.
      • 11.5.5.1. Overview,
      • 11.5.5.2. Products & services,
      • 11.5.5.3. SWOT analysis,
      • 11.5.5.4. Recent developments,
      • 11.5.5.5. strategies,
      • 11.5.5.6. financials (based on availability)
    • 11.5.6. ONO PHARMACEUTICAL CO., LTD.
      • 11.5.6.1. Overview,
      • 11.5.6.2. Products & services,
      • 11.5.6.3. SWOT analysis,
      • 11.5.6.4. Recent developments,
      • 11.5.6.5. strategies,
      • 11.5.6.6. financials (based on availability)
    • 11.5.7. Janssen Pharmaceuticals, Inc.
      • 11.5.7.1. Overview,
      • 11.5.7.2. Products & services,
      • 11.5.7.3. SWOT analysis,
      • 11.5.7.4. Recent developments,
      • 11.5.7.5. strategies,
      • 11.5.7.6. financials (based on availability)
    • 11.5.8. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
      • 11.5.8.1. Overview,
      • 11.5.8.2. Products & services,
      • 11.5.8.3. SWOT analysis,
      • 11.5.8.4. Recent developments,
      • 11.5.8.5. strategies,
      • 11.5.8.6. financials (based on availability)
    • 11.5.9. CELGENE CORPORATION (Bristol Myers Squibb Company)
      • 11.5.9.1. Overview,
      • 11.5.9.2. Products & services,
      • 11.5.9.3. SWOT analysis,
      • 11.5.9.4. Recent developments,
      • 11.5.9.5. strategies,
      • 11.5.9.6. financials (based on availability)
    • 11.5.10. AbbVie Inc.
      • 11.5.10.1. Overview,
      • 11.5.10.2. Products & services,
      • 11.5.10.3. SWOT analysis,
      • 11.5.10.4. Recent developments,
      • 11.5.10.5. strategies,
      • 11.5.10.6. financials (based on availability)
    • 11.5.11. Sanofi
      • 11.5.11.1. Overview,
      • 11.5.11.2. Products & services,
      • 11.5.11.3. SWOT analysis,
      • 11.5.11.4. Recent developments,
      • 11.5.11.5. strategies,
      • 11.5.11.6. financials (based on availability)
    • 11.5.12. Other Prominent Players
      • 11.5.12.1. Overview,
      • 11.5.12.2. Products & services,
      • 11.5.12.3. SWOT analysis,
      • 11.5.12.4. Recent developments,
      • 11.5.12.5. strategies,
      • 11.5.12.6. financials (based on availability)

12. Strategic Recommendation

List of Tables

  • Table 1: Global Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 3: Global Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Region, 2021-2034
  • Table 4: North America Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 5: North America Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 6: North America Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country, 2021-2034
  • Table 7: Europe Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 8: Europe Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 9: Europe Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 10: Asia Pacific Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 11: Asia Pacific Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Asia Pacific Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Latin America Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 14: Latin America Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Latin America Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Middle East & Africa Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Drug Class, 2021-2034
  • Table 17: Middle East & Africa Multiple Myeloma Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Middle East & Africa Multiple Myeloma Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Multiple Myeloma Market Revenue Breakdown (US$ Bn, %) by Region, 2025 & 2034
  • Figure 2: Global Multiple Myeloma Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Multiple Myeloma Market Forecast (US$ Bn), by Immunomodulators, 2021-2034
  • Figure 4: Global Multiple Myeloma Market Forecast (US$ Bn), by Proteasome Inhibitor, 2021-2034
  • Figure 5: Global Multiple Myeloma Market Forecast (US$ Bn), by Anti-CD38 Monoclonal Antibody, 2021-2034
  • Figure 6: Global Multiple Myeloma Market Forecast (US$ Bn), by Alkylating Agents, 2021-2034
  • Figure 7: Global Multiple Myeloma Market Forecast (US$ Bn), by Others, 2021-2034
  • Figure 8: Global Multiple Myeloma Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 9: Global Multiple Myeloma Market Forecast (US$ Bn), by Hospital Pharmacies, 2021-2034
  • Figure 10: Global Multiple Myeloma Market Forecast (US$ Bn), by Retail Pharmacies & Drug Stores, 2021-2034
  • Figure 11: Global Multiple Myeloma Market Forecast (US$ Bn), by Online Pharmacies, 2021-2034
  • Figure 12: Global Multiple Myeloma Market Value (US$ Bn), by Region, 2025 & 2034
  • Figure 13: North America Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 14: North America Multiple Myeloma Market Value Share (%), by Drug Class, 2025
  • Figure 15: North America Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 16: North America Multiple Myeloma Market Value Share (%), by Distribution Channel, 2025
  • Figure 17: North America Multiple Myeloma Market Value (US$ Bn), By Country, 2025 & 2034
  • Figure 18: North America Multiple Myeloma Market Value Share (%), By Country, 2025
  • Figure 19: Europe Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 20: Europe Multiple Myeloma Market Value Share (%), by Drug Class, 2025
  • Figure 21: Europe Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 22: Europe Multiple Myeloma Market Value Share (%), by Distribution Channel, 2025
  • Figure 23: Europe Multiple Myeloma Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
  • Figure 24: Europe Multiple Myeloma Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 25: Asia Pacific Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 26: Asia Pacific Multiple Myeloma Market Value Share (%), by Drug Class, 2025
  • Figure 27: Asia Pacific Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 28: Asia Pacific Multiple Myeloma Market Value Share (%), by Distribution Channel, 2025
  • Figure 29: Asia Pacific Multiple Myeloma Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
  • Figure 30: Asia Pacific Multiple Myeloma Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 31: Latin America Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 32: Latin America Multiple Myeloma Market Value Share (%), by Drug Class, 2025
  • Figure 33: Latin America Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 34: Latin America Multiple Myeloma Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Latin America Multiple Myeloma Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Latin America Multiple Myeloma Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Middle East & Africa Multiple Myeloma Market Value (US$ Bn), by Drug Class, 2025 & 2034
  • Figure 38: Middle East & Africa Multiple Myeloma Market Value Share (%), by Drug Class, 2025
  • Figure 39: Middle East & Africa Multiple Myeloma Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
  • Figure 40: Middle East & Africa Multiple Myeloma Market Value Share (%), by Distribution Channel, 2025
  • Figure 41: Middle East & Africa Multiple Myeloma Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
  • Figure 42: Middle East & Africa Multiple Myeloma Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 43: Global Multiple Myeloma Market Share (%), By Company, 2025